Medicago inc.
$169,872,474.00 CAD
- Program
- SIF Stream3- Attraction
- Recipient country
- Canada
- Fiscal year
- 2019-2020
- Agreement period
- March 28, 2020 – March 31, 2024
- Reference
- ic:033-2020-2021-Q3-815733
Published purpose
The Project is in direct response to the global fight against COVID-19. The Project will be undertaken in two stages to (1) develop a plant-derived virus-like particle (VLP) vaccine for the prevention of COVID-19; and (2) establish a large-scale GMP Facility for vaccine and antibody production in Canada.
In plain English AI-generated
This federal contribution supports Medicago Inc. in developing a plant-derived COVID-19 vaccine and building a large-scale manufacturing facility for vaccines and antibodies in Canada.
Category: Health Primarily funds activity in Canada
Based on the published description. See how AI categorization works — the linked official record is authoritative.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.